BofA Securities has resumed coverage of Kenvue Inc (NYSE:KVUE) with no rating, citing the company’s pending acquisition by Kimberly-Clark. Despite reporting fourth-quarter organic sales growth and impressive gross profit margins, Kenvue’s stock is not trading on fundamentals due to the impending acquisition. The consumer health company, valued at $35.27 billion, operates with moderate debt and offers a 4.51% dividend yield.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
BofA Securities resumes Kenvue stock coverage with no rating
BofA Securities has resumed coverage of Kenvue Inc (NYSE:KVUE) with no rating, citing the company’s pending acquisition by Kimberly-Clark. Despite reporting fourth-quarter organic sales growth and impressive gross profit margins, Kenvue’s stock is not trading on fundamentals due to the impending acquisition. The consumer health company, valued at $35.27 billion, operates with moderate debt and offers a 4.51% dividend yield.